Monohydroxylated metabolites of the K2 synthetic cannabinoid JWH-073 retain intermediate to high cannabinoid 1 receptor (CB1R) affinity and exhibit neutral antagonist to partial agonist activity

Biochemical Pharmacology

Volumn 83, Issue 7, 2012, Pages 952-961

  Brents, Lisa K ^a   Gallus Zawada, Anna ^a   Radominska Pandya, Anna ^a   Vasiljevik, Tamara ^b   Prisinzano, Thomas E ^b   Fantegrossi, William E ^a   Moran, Jeffery H ^a,c   Prather, Paul L ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b UNIVERSITY OF KANSAS   (United States)

^c ARKANSAS DEPARTMENT OF HEALTH   (United States)

Author keywords

Cannabinoid; CB1; JWH 073; K2 Spice; Obesity; Synthetic cannabis

Indexed keywords

(1 BUTYL 1H INDOLE 3 YL) 1 NAPHTHALENYL METHANONE; (1 BUTYL 4 HYDROXY 1H INDOLE 3 YL)(NAPHTHALEN 1 YL METHANONE); (1 BUTYL 6 HYDROXY 1H INDOLE 3 YL)(NAPHTHALEN 1 YL METHANONE); (1 BUTYL 7 HYDROXY 1H INDOLE 3 YL)(NAPHTHALEN 1 YL METHANONE); 1 (4 HYDROXYBUTYL 1H INDOLE 3 YL)(NAPHTHALEN 1 YL) METHANONE; 4 [3 (1 NAPHTHOYL) 1H INDOLE 1 YL] 1 BUTANOIC ACID; CANNABINOID 1 RECEPTOR; CANNABINOID 1 RECEPTOR AGONIST; CANNABINOID 1 RECEPTOR ANTAGONIST; CANNABINOID DERIVATIVE; DRUG METABOLITE; GUANINE NUCLEOTIDE BINDING PROTEIN; JWH 073; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; BRAIN HOMOGENATE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG METABOLISM; HYPOTHESIS; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; RECEPTOR AFFINITY; RECEPTOR BINDING;

ANIMALS; BEHAVIOR, ANIMAL; BINDING, COMPETITIVE; BODY TEMPERATURE; BRAIN; CANNABINOIDS; CELL MEMBRANE; DRUG ANTAGONISM; DRUG PARTIAL AGONISM; GTP-BINDING PROTEINS; HYDROXYLATION; INDOLES; LIGANDS; MALE; MICE; MICE, INBRED STRAINS; MOLECULAR STRUCTURE; NAPHTHALENES; PROTEIN BINDING; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, CANNABINOID, CB1; STREET DRUGS;

EID: 84857372061     PISSN: 00062952     EISSN: 18732968     Source Type: Journal    
DOI: 10.1016/j.bcp.2012.01.004     Document Type: Article

References (72)

1. I. Vardakou, C. Pistos, and C. Spiliopoulou Spice drugs as a new trend: mode of action, identification and legislation Toxicol Lett 197 2010 157 162
2. V. Auwarter, S. Dresen, W. Weinmann, M. Muller, M. Putz, and N. Ferreiros 'Spice' and other herbal blends: harmless incense or cannabinoid designer drugs J Mass Spectrom 44 2009 832 837
3. K.A. Seely, P.L. Prather, L.P. James, and J.H. Moran Marijuana-based drugs: innovative therapeutics or designer drugs of abuse Mol Interv 11 2011 36 51
4. S. Hudson, J. Ramsey, L. King, S. Timbers, S. Maynard, and P.I. Dargan Use of high-resolution accurate mass spectrometry to detect reported and previously unreported cannabinomimetics in herbal high products J Anal Toxicol 34 2010 252 260
5. R. Vandrey, K.E. Dunn, J.A. Fry, and E.R. Girling A survey study to characterize use of Spice products (synthetic cannabinoids) Drug Alcohol Depend 120 2012 238 241
6. D. Vearrier, and K.C. Osterhoudt A teenager with agitation: higher than she should have climbed Pediatr Emerg Care 26 2010 462 465
7. H. Muller, W. Sperling, M. Kohrmann, H.B. Huttner, J. Kornhuber, and J.M. Maler The synthetic cannabinoid Spice as a trigger for an acute exacerbation of cannabis induced recurrent psychotic episodes Schizophr Res 118 2010 309 310
8. H. Muller, H.B. Huttner, M. Kohrmann, J.E. Wielopolski, J. Kornhuber, and W. Sperling Panic attack after spice abuse in a patient with ADHD Pharmacopsychiatry 43 2010 152 153
9. S. Every-Palmer Synthetic cannabinoid JWH-018 and psychosis: an explorative study Drug Alcohol Depend 117 2011 152 157
10. A.C. Young, E. Schwarz, G. Medina, A. Obafemi, S.Y. Feng, and C. Kane Cardiotoxicity associated with the synthetic cannabinoid, K9, with laboratory confirmation Am J Emerg Med 2011 10.1016/j.ajem.2011.05.013
11. J. Simmons, L. Cookman, C. Kang, and C. Skinner Three cases of spice exposure Clin Toxicol (Phila) 49 2011 431 433
12. A.B. Schneir, J. Cullen, and B.T. Ly Spice girls: synthetic cannabinoid intoxication J Emerg Med 40 2011 296 299
13. J. Wehrman Fake marijuana spurs more than 4,500 calls to U.S. poison centers 2011 American Association of Poison Control Centers Alexandria, VA [accessed 12 May 2011]
14. M.M. Leonhart Schedules of controlled substances: temporary placement of five synthetic cannabinoids into schedule I 2010 Federal Register p. 71635-8 [accessed 3 January 2011]
15. AAPCC. Synthetic marijuana data, ; 2011 [accessed 17 December 2011].
16. X. Hu, B.A. Primack, T.E. Barnett, and R.L. Cook College students and use of K2: an emerging drug of abuse in young persons Subst Abuse Treat Prev Policy 6 2011 16
17. L.D. Johnston, P.M. O'Malley, J.G. Bachman, and J.E. Schulenberg Marijuana use continues to rise among U.S. teens, while alcohol use hits historic lows 2011 University of Michigan News Service Ann Arbor, MI [accessed 16 December 2011]
18. B.K. Atwood, J. Huffman, A. Straiker, and K. Mackie JWH018, a common constituent of 'Spice' herbal blends, is a potent and efficacious cannabinoid CB receptor agonist Br J Pharmacol 160 2010 585 593
19. T.U. Jarbe, H. Deng, S.K. Vadivel, and A. Makriyannis Cannabinergic aminoalkylindoles, including AM678=JWH018 found in 'Spice', examined using drug (Delta9-tetrahydrocannabinol) discrimination for rats Behav Pharmacol 22 2011 498 507
20. H.M. Wu, Y.M. Yang, and S.G. Kim Rimonabant, a CB1 inverse agonist, inhibits hepatocyte lipogenesis by activating LKB1 and AMPK axis downstream of G{alpha}i/o inhibition Mol Pharmacol 80 2011 859 869
21. K.A. Lindborg, M.K. Teachey, S. Jacob, and E.J. Henriksen Effects of in vitro antagonism of endocannabinoid-1 receptors on the glucose transport system in normal and insulin-resistant rat skeletal muscle Diabetes Obes Metab 12 2010 722 730
22. V. Di Marzo, and F. Piscitelli Gut feelings about the endocannabinoid system Neurogastroenterol Motil 23 2011 391 398
23. F. Rossi, G. Bellini, L. Luongo, M. Torella, S. Mancusi, and L. De Petrocellis The endovanilloid/endocannabinoid system: a new potential target for osteoporosis therapy Bone 48 2011 997 1007
24. M. Bari, N. Battista, V. Pirazzi, and M. Maccarrone The manifold actions of endocannabinoids on female and male reproductive events Front Biosci 16 2011 498 516
25. S. Dresen, N. Ferreiros, M. Putz, F. Westphal, R. Zimmermann, and V. Auwarter Monitoring of herbal mixtures potentially containing synthetic cannabinoids as psychoactive compounds J Mass Spectrom 45 2010 1186 1194
26. T. Sobolevsky, I. Prasolov, and G. Rodchenkov Detection of JWH-018 metabolites in smoking mixture post-administration urine Forensic Sci Int 200 2010 141 147
27. K.C. Chimalakonda, C.L. Moran, P.D. Kennedy, G.W. Endres, A. Uzieblo, and P.J. Dobrowolski Solid-phase extraction and quantitative measurement of omega and omega-1 metabolites of JWH-018 and JWH-073 in human urine Anal Chem 83 2011 6381 6388
28. C.L. Moran, V.H. Le, K.C. Chimalakonda, A.L. Smedley, F.D. Lackey, and S.N. Owen Quantitative measurement of JWH-018 and JWH-073 metabolites excreted in human urine Anal Chem 83 2011 4228 4236
29. N. Uchiyama, R. Kikura-Hanajiri, J. Ogata, and Y. Goda Chemical analysis of synthetic cannabinoids as designer drugs in herbal products Forensic Sci Int 198 2010 31 38
30. H.J. Penn, L.J. Langman, D. Unold, J. Shields, and J.H. Nichols Detection of synthetic cannabinoids in herbal incense products Clin Biochem 44 2011 1163 1165
31. J.W. Huffman, D. Dai, B.R. Martin, and D.R. Compton Design, synthesis, and pharmacology of cannabimimetic indoles Bioorg Med Chem Lett 4 1994 563 566
32. Drugs-Forum JWH-018 or JWH-073, which do you prefer? 2009 Substance Information Network (S.I.N.) Foundation [accessed 07 August 2011]
33. I. Moller, A. Wintermeyer, K. Bender, M. Jubner, A. Thomas, and O. Krug Screening for the synthetic cannabinoid JWH-018 and its major metabolites in human doping controls Drug Test Anal 3 2011 609 620
34. A. Grigoryev, S. Savchuk, A. Melnik, N. Moskaleva, J. Dzhurko, and M. Ershov Chromatography-mass spectrometry studies on the metabolism of synthetic cannabinoids JWH-018 and JWH-073, psychoactive components of smoking mixtures J Chromatogr B Analyt Technol Biomed Life Sci 879 2011 1126 1136
35. L.K. Brents, E.E. Reichard, S.M. Zimmerman, J.H. Moran, W.E. Fantegrossi, and P.L. Prather Phase I hydroxylated metabolites of the K2 synthetic cannabinoid JWH-018 retain in vitro and in vivo cannabinoid 1 receptor affinity and activity PLoS ONE 6 2011 e21917
36. J.W. Huffman, G. Zengin, M.J. Wu, J. Lu, G. Hynd, and K. Bushell Structure-activity relationships for 1-alkyl-3-(1-naphthoyl)indoles at the cannabinoid CB(1) and CB(2) receptors: steric and electronic effects of naphthoyl substituents. New highly selective CB(2) receptor agonists Bioorg Med Chem 13 2005 89 112
37. T. Qi, W. Qiu, Y. Liu, H. Zhang, X. Gao, and Y. Liu Synthesis, structures, and properties of disubstituted heteroacenes on one side containing both pyrrole and thiophene rings J Org Chem 73 2008 4638 4643
38. J.R. Denton One-pot desulfonylative alkylation of n-sulfonyl azacycles using alkoxides generated by phase-transfer catalysis Synthesis 5 2010 775 782
39. P.L. Prather, N.A. Martin, C.S. Breivogel, and S.R. Childers Activation of cannabinoid receptors in rat brain by WIN 55212-2 produces coupling to multiple G protein alpha-subunits with different potencies Mol Pharmacol 57 2000 1000 1010
40. J.L. Shoemaker, B.K. Joseph, M.B. Ruckle, P.R. Mayeux, and P.L. Prather The endocannabinoid noladin ether acts as a full agonist at human CB2 cannabinoid receptors J Pharmacol Exp Ther 314 2005 868 875
41. Y. Cheng, and W.H. Prusoff Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction Biochem Pharmacol 22 1973 3099 3108
42. H.C. Cheng The power issue: determination of KB or Ki from IC50. A closer look at the Cheng-Prusoff equation, the Schild plot and related power equations J Pharmacol Toxicol Methods 46 2001 61 71
43. A. Thomas, L.A. Stevenson, K.N. Wease, M.R. Price, G. Baillie, and R.A. Ross Evidence that the plant cannabinoid Delta9-tetrahydrocannabivarin is a cannabinoid CB1 and CB2 receptor antagonist Br J Pharmacol 146 2005 917 926
44. M.M. Aung, G. Griffin, J.W. Huffman, M. Wu, C. Keel, and B. Yang Influence of the N-1 alkyl chain length of cannabimimetic indoles upon CB(1) and CB(2) receptor binding Drug Alcohol Depend 60 2000 133 140
45. P.B. Smith, D.R. Compton, S.P. Welch, R.K. Razdan, R. Mechoulam, and B.R. Martin The pharmacological activity of anandamide, a putative endogenous cannabinoid, in mice J Pharmacol Exp Ther 270 1994 219 227
46. M.A. Huestis Human cannabinoid pharmacokinetics Chem Biodivers 4 2007 1770 1804
47. B.K. Atwood, D. Lee, A. Straiker, T.S. Widlanski, and K. Mackie CP47,497-C8 and JWH073, commonly found in 'Spice' herbal blends, are potent and efficacious CB(1) cannabinoid receptor agonists Eur J Pharmacol 659 2011 139 145
48. L. Mikasova, L. Groc, D. Choquet, and O.J. Manzoni Altered surface trafficking of presynaptic cannabinoid type 1 receptor in and out synaptic terminals parallels receptor desensitization Proc Natl Acad Sci USA 105 2008 18596 18601
49. J.J. Burston, J.L. Wiley, A.A. Craig, D.E. Selley, and L.J. Sim-Selley Regional enhancement of cannabinoid CB₁ receptor desensitization in female adolescent rats following repeated Delta-tetrahydrocannabinol exposure Br J Pharmacol 161 2010 103 112
50. B.B. Gorzalka, and M.N. Hill Putative role of endocannabinoid signaling in the etiology of depression and actions of antidepressants Prog Neuropsychopharmacol Biol Psychiatry 35 2011 1575 1585
51. C. Li, P.M. Jones, and S.J. Persaud Role of the endocannabinoid system in food intake, energy homeostasis and regulation of the endocrine pancreas Pharmacol Ther 129 2011 307 320
52. B.A. Watkins, H. Hutchins, Y. Li, and M.F. Seifert The endocannabinoid signaling system: a marriage of PUFA and musculoskeletal health J Nutr Biochem 21 2010 1141 1152
53. M. Karst, S. Wippermann, and J. Ahrens Role of cannabinoids in the treatment of pain and (painful) spasticity Drugs 70 2010 2409 2438
54. T. Bisogno, and V. Di Marzo Cannabinoid receptors and endocannabinoids: role in neuroinflammatory and neurodegenerative disorders CNS Neurol Disord Drug Targets 9 2010 564 573
55. B.B. Gorzalka, M.N. Hill, and S.C. Chang Male-female differences in the effects of cannabinoids on sexual behavior and gonadal hormone function Horm Behav 58 2010 91 99
56. D. Jutras-Aswad, J.A. DiNieri, T. Harkany, and Y.L. Hurd Neurobiological consequences of maternal cannabis on human fetal development and its neuropsychiatric outcome Eur Arch Psychiatry Clin Neurosci 259 2009 395 412
57. R.J. McKallip, M. Nagarkatti, and P.S. Nagarkatti Delta-9- tetrahydrocannabinol enhances breast cancer growth and metastasis by suppression of the antitumor immune response J Immunol 174 2005 3281 3289
58. M. Haney The marijuana withdrawal syndrome: diagnosis and treatment Curr Psychiatry Rep 7 2005 360 366
59. D.J. Allsop, M.M. Norberg, J. Copeland, S. Fu, and A.J. Budney The Cannabis Withdrawal Scale development: patterns and predictors of cannabis withdrawal and distress Drug Alcohol Depend 119 2011 123 129
60. J. Hirvonen, R.S. Goodwin, C.T. Li, G.E. Terry, S.S. Zoghbi, and C. Morse Reversible and regionally selective downregulation of brain cannabinoid CB(1) receptors in chronic daily cannabis smokers Mol Psychiatry 2011 10.1038/mp.2011.82
61. A.J. Budney, and J.R. Hughes The cannabis withdrawal syndrome Curr Opin Psychiatry 19 2006 233 238
62. R. Vandrey, A. Umbricht, and E.C. Strain Increased blood pressure after abrupt cessation of daily cannabis use J Addict Med 5 2011 16 20
63. Drugs-Forum JWH-073 experiences 2009 Substance Information Network (S.I.N.) Foundation [accessed 08 August 2011]
64. V. Di Marzo, and I. Matias Endocannabinoid control of food intake and energy balance Nat Neurosci 8 2005 585 589
65. C.E. Beyer, J.M. Dwyer, M.J. Piesla, B.J. Platt, R. Shen, and Z. Rahman Depression-like phenotype following chronic CB1 receptor antagonism Neurobiol Dis 39 2010 148 155
66. F.A. Moreira, M. Grieb, and B. Lutz Central side-effects of therapies based on CB1 cannabinoid receptor agonists and antagonists: focus on anxiety and depression Best Pract Res Clin Endocrinol Metab 23 2009 133 144
67. J. Bergman, M.S. Delatte, C.A. Paronis, K. Vemuri, G.A. Thakur, and A. Makriyannis Some effects of CB1 antagonists with inverse agonist and neutral biochemical properties Physiol Behav 93 2008 666 670
68. R.G. Pertwee Pharmacological actions of cannabinoids Handb Exp Pharmacol 2005 1 51
69. N.L. Cluny, A.P. Chambers, V.K. Vemuri, J.T. Wood, L.K. Eller, and C. Freni The neutral cannabinoid CB receptor antagonist AM4113 regulates body weight through changes in energy intake in the rat Pharmacol Biochem Behav 97 2010 537 543
70. K.S. Sink, K.N. Segovia, L.E. Collins, E.J. Markus, V.K. Vemuri, and A. Makriyannis The CB1 inverse agonist AM251, but not the CB1 antagonist AM4113, enhances retention of contextual fear conditioning in rats Pharmacol Biochem Behav 95 2010 479 484
71. G. Kunos, D. Osei-Hyiaman, S. Batkai, K.A. Sharkey, and A. Makriyannis Should peripheral CB(1) cannabinoid receptors be selectively targeted for therapeutic gain Trends Pharmacol Sci 30 2009 1 7
72. J. Tam, V.K. Vemuri, J. Liu, S. Batkai, B. Mukhopadhyay, and G. Godlewski Peripheral CB1 cannabinoid receptor blockade improves cardiometabolic risk in mouse models of obesity J Clin Invest 120 2010 2953 2966